{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:47:23Z","timestamp":1754164043407,"version":"3.41.2"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031584","name":"German Centre for Diabetes Research","doi-asserted-by":"crossref","award":["82DZD14A02"],"award-info":[{"award-number":["82DZD14A02"]}],"id":[{"id":"10.13039\/100031584","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abbott","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010215","name":"German Diabetes Society","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010215","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2021,3,28]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The aims of this study were to characterize insulin-treated individuals aged \u226575 years with type 2 diabetes using basal insulin analogs (BIA) or regular insulins (human insulin (HI)\/neutral protamine Hagedorn (NPH)) and to compare the benefits and risks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>The analysis was based on data from the DPV (Diabetes-Patienten-Verlaufsdokumentation) and DIVE (DIabetes Versorgungs-Evaluation) registries. To balance for confounders, propensity score matching for age, sex, diabetes duration, body mass index and hemoglobin A1c (HbA1c) as covariates was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 167 300 patients aged \u226575 years with type 2 diabetes (mean age, 80.3 years), 9601 subjects used insulin regimens with basal insulin (HI\/NPH or BIA). Of these 8022 propensity score-matched subjects were identified. The mean diabetes duration was ~12 years and half of the patients were male. At the time of switch, patients provided with BIA experienced more dyslipidemia (89.3% vs 85.9%; p=0.002) and took a greater number of medications (4.3 vs 3.7; p&lt;0.001) and depression was more prevalent (8.4% vs 6.5%; p=0.01). Aggregated to the most actual treatment year, BIA was associated with a higher percentage of patients using basal-supported oral therapy (42.6% vs 14.4%) and intensified conventional insulin therapy (44.3% vs 29.4%) and lower total daily insulin doses (0.24 IU\/kg\/day vs 0.30 IU\/kg\/day; p&lt;0.001). The study did not reveal significant differences in efficacy (HbA1c 7.4% vs 7.3%; p=0.06), hospitalizations (0.7 vs 0.8 per patient-year (PY); p=0.15), length of stay (16.3 vs 16.1 days per PY; p=0.53), or rates of severe hypoglycemia (4.07 vs 4.40 per 100 PY; p=0.88), hypoglycemia with coma (3.64 vs 3.26 per 100 PY; p=0.88) and diabetic ketoacidosis (0.01 vs 0.03 per 100 PY; p=0.36).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BIA were used in more individually and patient-centered therapy regimens compared with HI\/NPH in patients with a mean age of 80 years. Both groups were slightly overtreated with mean HbA1c &lt;7.5%. The risk of severe hypoglycemia was low and independent of insulin type. Further analyses of elderly patients with type 2 diabetes are needed to provide evidence for best practice approaches in this age group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2021-002215","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T13:37:51Z","timestamp":1622727471000},"page":"e002215","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["DIVE\/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus"],"prefix":"10.1136","volume":"9","author":[{"given":"Gesine","family":"van Mark","sequence":"first","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha R","family":"Tittel","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany"},{"name":"German Center for Diabetes Research (DZD), M\u00fcnchen-Neuherberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Welp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Knappschaftskrankenhaus Bottrop, Bottrop, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Gloyer","sequence":"additional","affiliation":[{"name":"Center for Diabetes Ludwigsburg, Ludwigsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sziegoleit","sequence":"additional","affiliation":[{"name":"Specialized Diabetes Practice Berlin Tempelhof, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Barion","sequence":"additional","affiliation":[{"name":"Medical Practice for Internal Medicine and Diabetology Rhein-Sieg, Niederkassel-Rheidt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M","family":"Jehle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, University Medicine, Academic Hospital Paul-Gerhardt-Stift, Lutherstadt Wittenberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Erath","sequence":"additional","affiliation":[{"name":"Medical Practice for Internal Medicine Rottweil, Rottweil, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany"},{"name":"German Center for Diabetes Research (DZD), M\u00fcnchen-Neuherberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"2025073111404981000_9.1.e002215.1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00592-019-01409-3","article-title":"Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and dive registries","volume":"57","author":"Hartmann","year":"2020","journal-title":"Acta Diabetol"},{"key":"2025073111404981000_9.1.e002215.2","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820958296","article-title":"Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases","volume":"11","author":"van Mark","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2025073111404981000_9.1.e002215.3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamainternmed.2014.1824","article-title":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011","volume":"174","author":"Lipska","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2025073111404981000_9.1.e002215.4","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-122"},{"key":"2025073111404981000_9.1.e002215.5","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s13300-020-00925-8","article-title":"The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review","volume":"11","author":"Cheng","year":"2020","journal-title":"Diabetes Ther"},{"key":"2025073111404981000_9.1.e002215.6","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"2025073111404981000_9.1.e002215.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.04.007"},{"key":"2025073111404981000_9.1.e002215.8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12485"},{"key":"2025073111404981000_9.1.e002215.9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/03007995.2017.1298522","article-title":"The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes","volume":"33","author":"Lajara","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2025073111404981000_9.1.e002215.10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.diabres.2016.03.008","article-title":"Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria","volume":"115","author":"Bohn","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073111404981000_9.1.e002215.11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jpeds.2015.09.006","article-title":"Non-High-Density lipoprotein cholesterol in children with diabetes: proposed treatment recommendations based on glycemic control, body mass index, age, sex, and generally accepted cut points","volume":"167","author":"Schwab","year":"2015","journal-title":"J Pediatr"},{"key":"2025073111404981000_9.1.e002215.12","first-page":"934","article-title":"[\"DIabetes Versorgungs-Evaluation\" (DIVE)--a national quality assurance initiative at physicians providing care for patients with diabetes]","volume":"138","author":"Danne","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"key":"2025073111404981000_9.1.e002215.13","unstructured":"S2k-Leitlinie Diagnostik, therapie und Verlaufskontrolle des diabetes mellitus Im alter. AWMF-Registernummer: 057-017. Available: https:\/\/www.deutsche-diabetes-gesellschaft.de\/fileadmin\/Redakteur\/Leitlinien\/Evidenzbasierte_Leitlinien\/2018\/057_017_LL_Alter_Gesamtdokument_20180713.pdf [Accessed 18 Jan 2021]."},{"key":"2025073111404981000_9.1.e002215.14","unstructured":"Recommendations for managing type 2 diabetes in primary care. Available: www.idf.org\/managing-type2-diabetes [Accessed 4 October 2020]."},{"key":"2025073111404981000_9.1.e002215.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"2025073111404981000_9.1.e002215.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"2025073111404981000_9.1.e002215.17","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2010.0543"},{"key":"2025073111404981000_9.1.e002215.18","first-page":"427","article-title":"Diabetes control and complications trial (DCCT)","volume":"13","year":"1990","journal-title":"Update. DCCT Research Group. Diabetes care"},{"key":"2025073111404981000_9.1.e002215.19","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/clinchem\/33.12.2267","article-title":"Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: a multicenter study. The DCCT Research Group","volume":"33","year":"1987","journal-title":"Clin Chem"},{"key":"2025073111404981000_9.1.e002215.20","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1245"},{"key":"2025073111404981000_9.1.e002215.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.13994"},{"key":"2025073111404981000_9.1.e002215.22","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2025073111404981000_9.1.e002215.23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/dom.12783","article-title":"Dyslipidaemia and its treatment in patients with type 2 diabetes: a joint analysis of the German DIVE and DPV registries","volume":"19","author":"Bramlage","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025073111404981000_9.1.e002215.24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an endocrine Society* clinical practice guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073111404981000_9.1.e002215.25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.arcmed.2018.02.004","article-title":"Interaction between depression, obesity, and type 2 diabetes: a complex picture","volume":"48","author":"Sevilla-Gonz\u00e1lez","year":"2017","journal-title":"Arch Med Res"},{"key":"2025073111404981000_9.1.e002215.26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11769"},{"key":"2025073111404981000_9.1.e002215.27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/geront\/gnx018","article-title":"The German long-term care insurance program: evolution and recent developments","volume":"58","author":"Nadash","year":"2018","journal-title":"Gerontologist"},{"key":"2025073111404981000_9.1.e002215.28","unstructured":"Deutschlandergebnisse . Statistisches Bundesamt: Pflegestatistik, 2019. Available: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Pflege\/Publikationen\/Downloads-Pflege\/pflege-deutschlandergebnisse-5224001199004.pdf?__blob=publicationFile [Accessed 18 Jan 2021]."},{"key":"2025073111404981000_9.1.e002215.29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/a-1207-9645","article-title":"Charakteristika von Diabetespatienten mit und ohne Pflegebed\u00fcrftigkeit","volume":"15","author":"Hodeck","year":"2020","journal-title":"Diabetologie und Stoffwechsel"},{"key":"2025073111404981000_9.1.e002215.30","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0074"},{"key":"2025073111404981000_9.1.e002215.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S012"},{"key":"2025073111404981000_9.1.e002215.32","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13644"},{"key":"2025073111404981000_9.1.e002215.33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pcd.2015.01.011","article-title":"Treatment persistence after initiating basal insulin in type 2 diabetes patients: a primary care database analysis","volume":"9","author":"Pscherer","year":"2015","journal-title":"Prim Care Diabetes"},{"key":"2025073111404981000_9.1.e002215.34","unstructured":"Nationale Versorgungsleitlinie Typ-2-Diabetes, Langfassung, 2. Auflage, Konsultationsfassung. Available: https:\/\/www.leitlinien.de\/mdb\/downloads\/nvl\/diabetes-mellitus\/dm-2aufl-konsultation.pdf [Accessed 23 Jan 2021]."},{"key":"2025073111404981000_9.1.e002215.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0299"},{"key":"2025073111404981000_9.1.e002215.36","article-title":"(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus","volume":"11","author":"Semlitsch","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025073111404981000_9.1.e002215.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1441"},{"key":"2025073111404981000_9.1.e002215.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00915.x"},{"key":"2025073111404981000_9.1.e002215.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01165.x"},{"key":"2025073111404981000_9.1.e002215.40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03722.x"},{"key":"2025073111404981000_9.1.e002215.41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.2018.21364","article-title":"Implementation of a health plan program for switching from analogue to human insulin and glycemic control among Medicare beneficiaries with type 2 diabetes","volume":"321","author":"Luo","year":"2019","journal-title":"JAMA"},{"key":"2025073111404981000_9.1.e002215.42","article-title":"Short-Acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus","volume":"12","author":"Fullerton","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025073111404981000_9.1.e002215.43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamainternmed.2020.9176","article-title":"Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin","volume":"181","author":"Bradley","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025073111404981000_9.1.e002215.44","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.amjmed.2019.06.033","article-title":"The case for using human insulin","volume":"133","author":"Davidson","year":"2020","journal-title":"Am J Med"},{"key":"2025073111404981000_9.1.e002215.45","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy169"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2021-002215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:41:00Z","timestamp":1753987260000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2021-002215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,3]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjdrc-2021-002215"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2021-002215","relation":{},"ISSN":["2052-4897"],"issn-type":[{"type":"electronic","value":"2052-4897"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}